Zeng Yuyu, Gan Dakai, Zhang Kaige, Long Tao, He Yan, Zhou Rui, Liu Shuanglan, Xiong Molong
Infectious Diseases Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.167, Qingshan Lake Avenue, Nanchang, 330000, China.
The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, NO.17, Yongwai Zheng Street, Nanchang, 330000, China.
Hepatol Int. 2024 Oct;18(5):1540-1554. doi: 10.1007/s12072-024-10712-3. Epub 2024 Jul 20.
Acute-on-chronic liver failure (ACLF) patients exhibit an imbalance in intestinal microbiota, and bile acids (BAs) can affect the composition of intestinal microbiota. Although Artificial liver support system (ALSS) is a treatment for ACLF, the impact of ALSS on intestinal microbiota and serum BA profiles of ACLF patients remains unclear.
A prospective study was conducted, which included 51 patients diagnosed with ACLF. These patients were stratified into two groups based on the utilization of an ALSS during their treatment period: a standard medical treatment group (SMT group), comprising 19 patients, and an ALSS combined with SMT group (ALSS group), comprising 32 patients. Blood and stool samples were collected from the patients on the day of admission and 14 days after treatment. Additionally, eight healthy controls were recruited, and their stool samples were also collected. The intestinal microbiota was sequenced using the 16S rRNA sequencing technique, while the serum BA profiles were determined using ultra-performance liquid chromatography/mass spectrometry.
ACLF patients exhibited imbalances in intestinal microbiota and abnormalities in BA profiles. Compared to SMT alone, the combined ALSS and SMT was more effective in regulating intestinal microbiota imbalance and increasing the concentrations of ursodeoxycholic acid and glycoursodeoxycholic acid. Correlation analysis revealed a significant correlation between intestinal microbiota and Bas. Furthermore, the preliminary correlation heatmap indicated that the Faecalibaculum, Gemmiger, and taurochenodeoxycholic acid were associated with clinical improvement.
Our study identified the compositional characteristics of the intestinal microbiota and serum BA in ACLF patients, emphasizing the impact of ALSS on both intestinal microbiota and serum BA profiles.
慢加急性肝衰竭(ACLF)患者存在肠道微生物群失衡,胆汁酸(BAs)可影响肠道微生物群的组成。尽管人工肝支持系统(ALSS)是治疗ACLF的一种方法,但ALSS对ACLF患者肠道微生物群和血清BA谱的影响仍不清楚。
进行了一项前瞻性研究,纳入51例诊断为ACLF的患者。根据治疗期间是否使用ALSS将这些患者分为两组:标准药物治疗组(SMT组),共19例患者;ALSS联合SMT组(ALSS组),共32例患者。在患者入院当天和治疗后14天采集血液和粪便样本。此外,招募了8名健康对照者,并采集了他们的粪便样本。使用16S rRNA测序技术对肠道微生物群进行测序,同时使用超高效液相色谱/质谱法测定血清BA谱。
ACLF患者表现出肠道微生物群失衡和BA谱异常。与单纯SMT相比,ALSS联合SMT在调节肠道微生物群失衡和增加熊去氧胆酸和甘氨熊去氧胆酸浓度方面更有效。相关性分析显示肠道微生物群与BAs之间存在显著相关性。此外初步相关性热图表明,粪便杆菌属、Gemmiger菌属和牛磺鹅去氧胆酸与临床改善相关。
我们的研究确定了ACLF患者肠道微生物群和血清BA的组成特征,强调了ALSS对肠道微生物群和血清BA谱的影响。